surmount-1 tirzepatide non-diabetic weight loss Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 Read now: The SURPASS-EARLY trial
Description
The most frequently reported side effects of tirzepatide are gastrointestinal in nature, occurring in a substantial proportion of patients during clinical trials
Discontinue MOUNJARO if suspected and promptly seek medical advice
Tirzepatide injections are available through supervised medical weight loss clinics
Following its clinical trials and approval, the impact of tirzepatide on patients has been profound
An over-the-counter version of orlistat that you can buy without a prescription
